Top Markets
Coin of the day
Radiopharm Theranostics Limited Radiopharm Theranostics Limited

Radiopharm Theranostics Limited

RAD
Hisse Senetlerindeki Sıralama #30071
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company,... Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. Additionally, it is developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPµ glioblastoma diagnostic; and RAD602, a PTPµ glioblastoma therapeutic. The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.
Hisse Fiyatı
$0.00775813
Piyasa Değeri
$18.35M
Değişim (1 gün)
-8.33%
Değişim (1 yıl)
-51.93%
Ülke
AU
Ticaret Radiopharm Theranostics Limited (RAD)

Kategori

Radiopharm Theranostics Limited (RAD) için temettü verimi geçmişi
Radiopharm Theranostics Limited (hisse sembolü: RAD) temettü verimi (TTM) 2026 itibariyle: 0
Son 5 yılın ortalama temettü verimi: 0.00%
Radiopharm Theranostics Limited (RAD) için 2026 - 2026 arası temettü verimi geçmişi
Her yılın sonunda temettü verimi (TTM)
Yıl Temettü Verimi Değiştir
Sağlanan tarihler için yeterli veri yok.
Benzer şirketler veya rakiplerin temettü verimi (TTM)
Şirket Temettü Verimi Ülke
0.00%
US
0.00%
NL
3.12%
AU
0.00%
CH
0.48%
BE